Novo Nordisk (NVO) stock and Wegovy, the company's blockbuster weight-loss treatment, are under pressure as compounders chip away at sales of the pharma giant's linchpin drug.
But the Danish drugmak… [+10960 chars]
Can Novo And Its Linchpin Drug Make A Comeback? - Investor's Business Daily
Novo Nordisk stock remains under pressure this year. But the company is now launching Wegovy in MASH treatment.
By:ALLISON GATLIN, Investor's Business Daily
Source:Investor's Business Daily
Published:
Related News
Six viruses detected at high levels in Kansas community’s wastewater - hayspost.com
Image Pixaby Lawrence sees early flu peak as some health care provider
hays Post
My Friend Has Been Sucked Into One of the Darkest Groups in the Parenting Community. I Can’t Stand By Her. - Slate
This sucks.
Slate Magazine•Logan Sachon
My Rude, Nosy Mother-in-Law Just “Had” to Walk in On Us Having Sex. Our Sex Life Will Never Be the Same. - Slate
My husband hasn't been able to perform since.
Slate Magazine•Rich Juzwiak